...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Pulmonary pharmacology & therapeutics >Tiotropium for the treatment of stable chronic obstructive pulmonary disease: A systematic review with meta-analysis.
【24h】

Tiotropium for the treatment of stable chronic obstructive pulmonary disease: A systematic review with meta-analysis.

机译：噻托铵治疗稳定的慢性阻塞性肺疾病：荟萃分析的系统评价。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Current guidelines recommend the use of inhaled tiotropium in patients with stable chronic obstructive pulmonary disease (COPD). However, this statement is based on a relatively small number of randomized controlled trials (RCTs) and related systematic reviews. This review was undertaken to incorporate the more recent evidence available about the effectiveness of tiotropium bromide compared with placebo, iptratropium bromide or long-acting beta-agonists (LABAs), for the treatment of stable COPD patients. Data source: Medline, EMBASE, CINAHL, and the Cochrane Controlled Trials Register (to February 2006) were searched to identify all published RCTs. We also searched bibliographies of relevant articles. Results: Data from 13 RCT (6078 subjects, 80% male) showed that tiotropium reduced COPD-related exacerbations (OR=0.76; 95% CI: 0.68-0.87) and hospital admissions (OR=0.59; 95% CI: 0.47-0.73) compared with placebo. Also, tiotropium showed statistically significant improvement in lung function,including trough, average, and peak FEV(1) and FVC from baseline, compared with placebo and ipratropium. The administration of inhaled tiotropium lead to 30% reduction in COPD-related admissions (OR= 0.67; 95% CI: 0.46-0.98) compared with LABAs. Finally, increases in FEV(1) and FVC from baseline were significantly larger with tiotropium than with LABAs. Conclusions: This review clearly supports the beneficial effects of the use of tiotropium in stable moderate-to-severe COPD patients, and increases the evidence in favor of the superiority of tiotropium on LABAs.
机译：背景：目前的指南建议在稳定的慢性阻塞性肺疾病（COPD）患者中使用吸入噻托铵。但是，该声明基于相对较少的随机对照试验（RCT）和相关的系统评价。进行此综述的目的是纳入与噻托溴铵相比安慰剂，异丙托溴铵或长效β-激动剂（LABA）相比，噻托溴铵对稳定COPD患者有效的最新证据。数据来源：检索Medline，EMBASE，CINAHL和Cochrane对照试验注册簿（至2006年2月）以识别所有已发布的RCT。我们还搜索了相关文章的书目。结果：来自13个RCT（6078名受试者，80％的男性）的数据显示噻托溴铵减少了COPD相关性加重（OR = 0.76; 95％CI：0.68-0.87）和住院治疗（OR = 0.59; 95％CI：0.47-0.73） ）与安慰剂相比。此外，与安慰剂和异丙托铵相比，噻托溴铵显示出肺功能的统计学显着改善，包括谷值，平均值和峰值FEV（1）和FVC均较基线低。与LABAs相比，吸入噻托溴铵可使COPD相关的入院率降低30％（OR = 0.67; 95％CI：0.46-0.98）。最后，噻托溴铵的FEV（1）和FVC与基线相比的增加明显大于LABA。结论：本评价明确支持噻托溴铵对稳定的中重度COPD患者的有益作用，并增加了支持噻托溴铵对LABAs优势的证据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号